Member Info for Livedataaccount

Approaching is what I said. We are now approaching the middle of H2. It's in sight, within reach no helping some people on this board.

Invest the lot in a pre clinical aim biotech

About time too, we are now approaching the middle of H2!

Timster, it is not a good idea to borrow money to invest in aim!

Why is this phase 1 trial taking so long?

For the record I lay the blame at Alan for the length of the trial

CC has my full support going foward

Is this possibly the longest ever phase 1 trial in history?

Has anyone actually bothered to call Avacta and ask?

Surely that must be finishing soon

Would it be Avacta's decision to stop after cohort 3? Or FDA?

Thanks, hurst

Touk.

How many were you expecting to have progress free survival?

What is 'huge amounts of dox'?

Thanks, hurst

Difficult to argue with any of that

But worth mentioning the drug they do have in the clinic appears to be doing remarkably well.

The new CEO seems very driven and capable.

Clear milestones have been set for the remainder of the year, whixh I expect to be hit.

At this price it's a comfortable hold for me

Sorry to hear, vertizea.

Could be a whale buying in?

Thanks, Hurst

My understanding is ld and coris will be sold. Probably back into European hands?

Not sure what the scale of Avacta's in house diagnostics business actually is?

Agree, I am expecting a net loss but it's a positive move concentrating on tx overall

For those of you that are up at 7am praying for that takeover rns for the 600th day running

It's not always size that matters, Timster